| This week's sponsor is Bracket. | | | |
Featured Story Thursday, February 23, 2017 Editors at The BMJ have warned President Trump’s policies could damage biomedical research and regulation around the world. The journal has committed to fostering open debate and supporting those who “speak truth to power” to counter the actions of an administration it sees as heading for a “head-on collision with the scientific and health communities.”
Thursday, February 23, 2017 Cyclacel Pharmaceuticals has been taught the meaning of futility. Two years after an independent data monitoring board told Cyclacel its phase 3 acute myeloid leukemia (AML) trial was destined to fail, the ever-optimistic biotech has reported its drug sapacitabine was unable to better the active control in terms of overall survival. Thursday, February 23, 2017 Just 12 months ago, Incyte was hit with a major trial setback when its JAK inhibition drug for solid tumors flopped a key test. But since then the biotech has been looking to I-O combos and today it has broadened its reach with a new cancer immunotherapy deal with the University of Pennsylvania. Tuesday, February 21, 2017 From startups to leading global companies, Greater Fort Lauderdale provides a stimulating and supportive business environment for success in the life sciences. Thursday, February 23, 2017 Aveo inches closer to completing a crucial trial of its main asset tivozanib—almost four years after the FDA turned down the kidney cancer drug. Wednesday, February 22, 2017 PPD just formed a partnership with Frenova Renal Research, which is giving PPD access to its vast network of nephrology experts and patients. Wednesday, February 22, 2017 Immunexpress earned 510(k) clearance for its RNA-based clinical diagnostic that detects sepsis in critically ill patients. The test, which uses whole blood, returns results in a few hours. | This week's sponsor is RAPS. | | | |
| | | Tocagen has been given an FDA "Breakthrough" label for Toca 511 and Toca FC in patients with certain types of brain cancer. Statement Charity Beyond Type 1 has handed out a new grant to private biotech ViaCyte to help fund its work on cell replacement research for Type 1 diabetes patients. Release After a chat with the FDA, Resverlogix said the phase 2a study of its experimental medication in kidney dialysis will now be separated into two parts. Statement | |
|
Resources Presented By: Veeva Share your thoughts on the life sciences industry’s progress in reducing system and process complexity to improve study execution. The first 50 qualified respondents will receive a $10 Amazon gift card, as well as a $10 donation made to Doctors Without Borders in their name. Finish the survey today! Sponsored By: Veeva Learn over a dozen best practices for deploying a global content system. Read Whitepaper. Sponsored By: Veeva Gartner provides insightful research on preparing for IDMP compliance. Read Whitepaper. Sponsored By: Veeva Learn How to Create a Unified RIM Environment for IDMP. Find out. Sponsored By: Veeva The largest survey of TMF owners reveals drivers and trends in improving inspection readiness and shortening trial time. Sponsored By: Salesforce Learn how the healthcare and life science industry is using agile application development to drive innovation and accelerate their business with the Salesforce Platform. Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA | 